• Pentixapharm’s Q3 2026 net loss narrowed 29% year over year to €2.5 million.
• Revenue fell 82% year over year to €14,000.
• Cash and cash equivalents rose to €21.92 million at September 30, 2026.
• First patient enrollment in the PANDA Phase 3 study is now expected in Q1 2027, versus the second half of 2026 previously.
• The group cut its FY26 net loss forecast 40% to approximately €13 million, citing deferred and reduced costs and eliminated scheduled amortization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.